1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Relapsed Peripheral T-Cell Lymphoma: new trials by email Literature Review of Relapsed Peripheral T-Cell Lymphoma trials Research Report on Relapsed Peripheral T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Alisertib, Pralatrexate, Gemcitabine - Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 271 | 2012-06-11 | 2018-07-31 |
Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
10-propargyl-10-deazaaminopterin (1) · Gemcitabine (1) · MLN 8237 (1) · romidepsin (1)
Millennium Pharmaceuticals, Inc. (1)
Australia (1) · Austria (1) · Belarus (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Egypt (1) · France (1) · Germany (1) · Hungary (1) · Israel (1)